Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00229502
Status:
COMPLETED
Last Update Posted:
2012-03-23
First Post:
2005-09-27
Brief Title:
Cognitive Effects of Immunomodulatory Drugs in MS
Sponsor:
Sharon Lynch MD
Organization:
University of Kansas Medical Center
Study Overview
Official Title:
Comparison of the Cognitive Effects of Three Immunomodulatory Drugs in Relapsing-Remitting Multiple Sclerosis A Longitudinal Study
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to examine and compare changes in the specific thinking skills of patients with RRMS who are receiving treatment with one of three immunomodulatory medications Avonex Copaxone or Rebif
Detailed Description:
In addition this study will compare the patients personal view of how they are doing any changes in physical disability and the frequency and severity of relapses over the three year period
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None